Unternehmensübersicht
Creative Medical Technology Holdings, Inc. operates as a commercial-stage biotechnology enterprise dedicated to the development of novel biological therapeutics across key therapeutic areas including immunotherapy, endocrinology, urology, neurology, and orthopedics within the United States. The company is specifically recognized for offering CaverStem as a treatment option for erectile dysfunction, alongside other proprietary developments such as FemC. This entity functions within the broader Healthcare sector and the specialized Biotechnology industry, which focuses on the research and commercialization of biological agents to treat various medical conditions. In terms of scale, the company possesses a market capitalization of $8.17M and generates annual revenue of $6,000, supported by a workforce consisting of 4 employees. These financial metrics indicate that Creative Medical Technology Holdings, Inc. is a micro-cap entity with extremely limited revenue generation relative to its market valuation, suggesting a capital-intensive business model typical of early-stage biotech firms where significant value is attributed to intellectual property and pipeline potential rather than current cash flow or sales volume.
Finanzielle Gesundheit
The financial statements for the trailing twelve months reveal a revenue figure of $6,000 contrasted against a net income of $-5,995,008 and an EBITDA of $-6,019,487, highlighting a severe disconnect between top-line activity and bottom-line profitability. The substantial negative gap between the minimal revenue and the multi-million dollar net loss indicates a cost structure heavily weighted toward research, development, and operational expenses that far exceed current sales, a characteristic pattern for pre-revenue or low-revenue biotechnology companies. The company's free cash flow stands at $-3,751,198, which signifies a high burn rate that limits immediate financial flexibility and necessitates external capital raising to sustain operations. Marginal analysis shows a gross margin of 63.4%, reflecting the cost efficiency of producing its biological products, while the operating margin is reported at -64859.4% and the profit margin at 0.0%, both of which underscore the extreme operational losses incurred relative to sales. Regarding liquidity and leverage, the company holds $7.21M in cash against a debt obligation of $14,194, resulting in a debt-to-equity ratio of 0.19, which suggests a balance sheet that is highly conservative and minimally leveraged despite the operating losses. The current ratio is an exceptionally high 25.97, indicating robust short-term liquidity where current assets significantly dwarf current liabilities, providing a substantial buffer against immediate solvency risks. Return on Equity is calculated at -86.5% and Return on Assets at -53.0%, metrics that reveal management has not yet achieved positive returns on the capital invested, reflecting the developmental stage of the enterprise rather than poor management efficacy in a mature market context.
Bewertungsanalyse
Valuation multiples present a complex picture due to the company's lack of positive earnings, with the P/E Ratio (TTM) listed as N/A and a Forward P/E of -1.64, implying that the market prices the stock based on non-earnings fundamentals or future recovery expectations rather than current profitability. The Price to Book ratio is 1.09, indicating that the market values the company at approximately one dollar above its book value per share, a metric often used for capital-intensive firms but here suggesting a slight premium over the net asset value. Alternative valuation metrics such as the Price to Sales ratio of 1361.61 and an EV/EBITDA of -0.16 further illustrate that traditional earnings-based valuation models are not applicable, pointing instead to a valuation driven by strategic assets and pipeline potential rather than sales performance. The stock's trading range over the past year spans from a 52-Week Low of $1.50 to a 52-Week High of $6.25, meaning the current price sits at a level that reflects significant volatility within this wide band. The Beta of 1.99 indicates that the stock's price volatility is nearly double that of the broader market, exposing investors to substantially higher systemic risk compared to large-cap peers.
Growth & Income
The growth profile is characterized by a Revenue Growth (YoY) of 0.0% and an Earnings Growth (YoY) of N/A, illustrating that the company has not experienced year-over-year expansion in its top line and lacks reported earnings growth due to its negative income position. As a non-dividend payer, the company reports a Dividend Yield of N/A and a Payout Ratio of 0.0%, which confirms that no portion of earnings is distributed to shareholders, a standard practice for biotechnology firms at this stage that prioritize retaining capital for R&D. Consequently, the company reinvests all available resources, including its $7.21M cash reserve, into research and development activities rather than paying dividends to maintain shareholder income. The overall growth and income profile suggests a high-risk, high-potential trajectory where capital appreciation is the sole return mechanism, relying entirely on the successful commercialization of its biological therapeutics to transition from a cash-burning entity to a profitable one in the future.